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Abstract
Significance: Since the signing of the National Cancer Act in 1971, cancer still remains a major cause of death
despite significant progresses made in understanding the biology and treatment of the disease. After many years of
ostracism, the peculiar energy metabolism of tumors has been recognized as an additional phenotypic trait of the
cancer cell. Recent Advances: While the enhanced aerobic glycolysis of carcinomas has already been translated to
bedside for precise tumor imaging and staging of cancer patients, accepting that an impaired bioenergetic function
of mitochondria is pivotal to understand energy metabolism of tumors and in its progression is debated. However,
mitochondrial bioenergetics and cell death are tightly connected. Critical Issues: Recent clinical findings indicate
that H+-ATP synthase, a core component of mitochondrial oxidative phosphorylation, is repressed at both the
protein and activity levels in human carcinomas. This review summarizes the relevance that mitochondrial function
has to understand energy metabolism of tumors and explores the connection between the bioenergetic function of
the organelle and the activity of mitochondria as tumor suppressors. Future Directions: The reversible nature of
energy metabolism in tumors highlights the relevance that the microenvironment has for tumor progression.
Moreover, the stimulation of mitochondrial activity or the inhibition of glycolysis suppresses tumor growth. Future
research should elucidate the mechanisms promoting the silencing of oxidative phosphorylation in carcinomas. The
aim is the development of new therapeutic strategies tackling energy metabolism to eradicate tumors or at least, to
maintain tumor dormancy and transform cancer into a chronic disease. Antioxid. Redox Signal. 19, 285–298.
Introduction
Cancer is a complex genetic disease that drives thetransformation of normal cells into malignancy by the
accumulation of mutations in oncogenes and tumor sup-
pressor genes. Genetic changes largely account for the un-
limited replicative potential, sustained angiogenesis, evasion
of apoptosis, self-sufficiency in growth signals, insensitivity to
anti-growth signals, and tissue invasion and metastasis that
are characteristics of the phenotype of cancer cells (36).
However, genetic alterations cannot solely explain tumor
development, and it is accepted that the interaction of cancer
cells with the microenvironment, the immune system, and
other epigenetic events are relevant determinants in tumor
promotion (31, 36, 91). In fact, the tumor microenvironment
could act as a ‘‘double-edged sword’’ leading either to de-
stabilization of tissue homeostasis or to reversion of the ma-
lignant phenotype (9).
In recent years, energy metabolism has been rediscovered
in cancer biology. The particular aerobic metabolism expe-
rienced by cancer cells has been finally recognized as an
additional hallmark of the cancer cell phenotype (22, 36, 74).
The abnormal high aerobic glycolysis of tumors was first
observed by Otto Warburg many years ago (74). He sug-
gested that the increased aerobic glycolysis of tumors should
result from an impaired bioenergetic activity of mitochon-
dria (95, 96). Warburg’s hypothesis was heatedly debated
(74) but largely neglected until its rediscovery by the im-
plementation of tumor imaging with 18F-desoxyglucose
(18FDG) by positron emission tomography (PET) in the
clinical practice of oncology (53, 73).
In this review, we will emphasize the prominent role that
silencing the activity of mitochondrial oxidative phosphory-
lation has to promote tumor development. We will show that
interfering either at short- or long-term with H + -ATP syn-
thase is enough to illustrate the actuality of the original
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Warburg hypothesis regarding the metabolic phenotype of
cancer cells and tumors. We will highlight that the peculiar
energymetabolism of the cancer cell is a ‘‘reversible trait’’ (i.e.,
in the majority of carcinomas, it is not based on permanent
genetic changes). The reversibility and flexibility of energy
metabolism thus widens up its value as a therapeutic ap-
proach for cancer treatment.
An Ongoing Debate
If the induction of glycolysis in the majority of carcinomas
is nowadays unquestionable, the impairment of the bioener-
getic function of mitochondria in cancer cells is still a matter
of debate (19). Perhaps it stems from the idea that only
oncogene-driven metabolic changes could explain the switch
of energy metabolism in cancer and/or from the observation
that some cancer cells growing in culture rely on oxidative
phosphorylation as the main energy provision pathway.
Indeed, the activation of oncogenes and the inhibition of
tumor suppressors (myc, Akt, p53, HIF1-a, APC/C-Cdh1)
certainly affect energy metabolism and could account for
changes in metabolic flux (40) and in the expression of
enzymes of energy metabolism (15, 22). These genetic alter-
ations, which are present with more or less frequency in dif-
ferent carcinomas, could act pleiotropically to upregulate
aerobic glycolysis, but are not the main underlying cause of
the Warburg phenotype of carcinomas. Why? Because most
prevalent carcinomas (breast, lung, colon, esophageal, .)
independently of its tissue of origin, histological type, and
genetic alterations all have the same protein signature of
energy metabolism (1). Moreover, the Warburg phenotype is
reversible and could be acquired without any genetic alter-
ation, as wewill see in the following. Since the impact of cancer
genes in energy metabolism has been extensively reviewed
elsewhere (15, 22), wewill not refer to this point any further. In
fact, we consider that emphasizing the role of cancer genes
in energy metabolism provides a reductionist approach to
understand the role of mitochondria in cancer biology.
On the other hand, it has been documented that increased
energy production by glycolysis in response to aberrant
mitochondrial respiration accompanies the acquisition of
the fully transformed state (72). In apparent contrast, the
transformation of human mesenchymal stem cells (hMSC)
show increased dependence on oxidative phosphorylation
when growing in culture (29). However, when transformed
hMSC were implanted into nude mice, an increase in gly-
colysis and the downregulation of genes of the TCA cycle
was observed (29), suggesting the relevance of the micro-
environment for tumor progression. Similar findings have
been obtained in H-RasV12/E1A transformed cells where
the tumorigenic potential of the cells increases concurrently
with an enhancement of glycolysis and a diminished ac-
tivity of mitochondrial respiration (20). More recently, it has
been documented that the enhanced infiltration of gliomas
in the brain parenchyma parallels the suppression of mito-
chondrial biogenesis and an increased glycolysis (44).
Consistent with these findings, in vivo tumor progression
requires the previous selection of cancer cells with a cellular
phenotype in which the bioenergetic activity of mitochon-
dria is repressed (76). The acquisition of this metabolic trait
is not based on a permanent genetic change, rather it rep-
resents a reversible feature that results from the metabolic
adaptation of the cells to the milieu where tumor cells de-
velop in vivo (76).
Mammalian cells show large differences in the molecular
composition of their mitochondria (63). Hence, a certain de-
gree of diversity is conceivable in the relevance of the path-
ways that contribute to energy provision in cancer cells. In this
regard, recent findings suggest the existence of metabolic
complexity, a sort of metabolic symbiosis, in energy metabo-
lism between cancer cells of the same tumor (86) or between
cancer and stromal cells (99). Moreover, it has been proposed
that b-oxidation fuels energy metabolism in metastatic ovar-
ian cancer cells by the supply of fatty acids derived from
adipocytes of the omentum (65). These findings might sup-
port a different energy metabolism in primary and metastatic
cancer cells. Consistent with the complex role of mitochon-
drial activity in tumor development, we maintain that energy
metabolism represents a reversible adaptive phenotypic re-
sponse of the cancer cell to hypoxia and/or other agents of the
tumor microenvironment (9, 65, 80, 99) that needs to be fur-
ther investigated.
Metabolic Overview of Energy Metabolism
Glucose is the preferred metabolic substrate of most
mammalian cells and its breakdown in the cytoplasm and
in mitochondria provides the energy, reducing power
(NADPH), and building blocks required for cellular mainte-
nance and/or proliferation (Fig. 1). The catabolism of gluta-
mine is also relevant for cellular proliferation in some cancer
cells (Fig. 1) (15, 22). Normoxic cells oxidize most of the py-
ruvate to CO2 in the mitochondria, and the electrons collected
on NADH and FADH2 are transferred to the complexes of the
respiratory chain to generate the proton electrochemical gra-
dient used in oxidative phosphorylation for the synthesis of
ATP (Fig. 1). In nonproliferating cells, the demand for glucose
is low because the oxidation of glucose coupled to oxidative
phosphorylation provides a high yield of ATP and NADH
(15). In contrast, proliferating cancerous and noncancerous
cells boost the rate of glucose consumption because glycolysis
provides themetabolic intermediates andNADPHneeded for
biosynthetic purposes (15). In this situation, pyruvate is re-
duced to lactate with the purpose of regenerating the oxidized
form of NAD + for glycolysis to proceed because oxida-
tive phosphorylation is downregulated during progression
through the cell cycle (Fig. 1) (15). Similarly, when the cells
have a limited supply of oxygen or have a genetic or epige-
netic impairment that restrains oxidative phosphorylation,
glycolysis is also enhanced. The excess of lactate produced in
these situations is exported out of the cell, contributing to
the acidification of the cellular environment and metastatic
disease (12).
The Pivotal Role of the Mitochondrial H1-ATP
Synthase in Energy Conservation
In oxidative phosphorylation, ATP is synthesized from
ADP and Pi by the mitochondrial H + -ATP synthase (Fig. 1), a
reversible engine of the inner mitochondrial membrane that
synthesizes or hydrolyses ATP upon changes in cellular
conditions (Fig. 2). An efficient oxidative phosphorylation
requires an inner mitochondrial membrane with low proton
conductance to prevent the waste of energy and the constant
supply of ADP and Pi that are shuttled into the matrix of the
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organelle by the adenine nucleotide and phosphate carriers,
respectively (Fig. 1).
The mammalian H + -ATP synthase consists of two main
domains: a membrane-bound hydrophobic F0 portion, which
contains the proton channel, and a soluble F1 portion that
contains the catalytic b-F1-ATPase subunit that encloses the
adenine nucleotide binding sites (Fig. 2). Both regions are
linked together by a central and a peripheral stalk (Fig. 2) (87).
Table 1 summarizes the genes and stoichiometry of the sub-
units that participate in each of the F0 and F1 domains of the
human H + -ATP synthase. The biogenesis of H + -ATP syn-
thase requires the coordinated expression of nuclear and mi-
tochondrial genes (Table 1) being the assembly of the
holoenzyme assisted by ‘assembly factors’ that do not take
part of the final enzyme (Table 1). In normal cells, and under
phosphorylating conditions, the re-entrance of protons into
the mitochondrial matrix (Fig. 2) triggers the rotation of the c-
ring and of the attached central stalk that induces the con-
formational changes in the b-F1-ATPase subunit that drive the
synthesis of ATP (Fig. 2). The ATPase inhibitory factor 1 (IF1)
is a physiological inhibitor of H + -ATP synthase (77). More-
over, H + -ATP synthase has stable interactions with itself to
delineate a supramolecular level of organization of the
membrane (88). In this superstructure, H + -ATP synthase di-
mers tend to align ‘in ribbons’ imposing a high curvature to
the innermembrane contributing to define the cristae structure
of mitochondria (88).
Short-Term Regulation of Energy Metabolism
The cellular availability of ATP, NADH, and some meta-
bolic intermediates (citrate) coordinate at short-term the ac-
tivity of key enzymes of energy metabolism such as
phosphofructokinase in the glycolytic pathway and various of
the mitochondrial dehydrogenases (26), to limit the flux of
matter and the production of biological energy as it is being
demanded by the cell (Fig. 1). It has long been recognized that
the efficient production of biological energy by oxidative
phosphorylation determines the rates of glucose consumption
in eukaryotic cells (49). In fact, this was demonstrated years
ago in aerobic cells using 2,4-dinitrophenol (2,4-DNP), which
uncouples the proton gradient generated by respiration from
oxidative phosphorylation (49). Cells that are actively re-
spiring when treated with 2,4-DNP re-establish the high rates
of glucose consumption and lactate production that are ob-
served when the cells are grown in anaerobiosis (Fig. 3A).
Consistently, both normal and breast cancer cells significantly
increase their rates of aerobic glycolysis when the proton
gradient is collapsed by treatment with 2,4-DNP (Fig. 3B). The
inhibition of the H + -ATP synthase with oligomycin also in-
duces an increase in aerobic glycolysis in many cancer cells
(53, 76).
Remarkably, we have recently shown that the ATPase in-
hibitor IF1 whose expression is negligible in normal human
breast, colon, and lung tissues is highly overexpressed in all
FIG. 1. Overview of energy metabolism. The scheme shows the relevant pathways involved in the metabolism of glucose
and glutamine (blue lines). Glucose is catabolized by the pentose phosphate pathway (PPP) to obtain reducing power
(NADPH) and ribose for nucleic acid biosynthesis and oxidize by glycolysis to generate pyruvate and other metabolic
intermediates. In the cytoplasm, the generated pyruvate can be reduced to lactate and further exported from the cell or
completely oxidized in the mitochondria by the tricarboxylic acid cycle (TCA cycle). The transfer of electrons obtained in
oxidations (NADH/FADH2) to molecular oxygen by respiratory complexes (green) of the inner mitochondrial membrane is
depicted by light blue lines. The formation of the proton gradient generated by respiration and its utilization for the synthesis
of ATP by the H + -ATP synthase in oxidative phosphorylation is highlighted by a red circuit. The entrance of ADP in exchange
with ATP by the adenine nucleotide translocase (ANT) and inorganic phosphate is also shown (yellow lines). Metabolic
activity utilizes carbon skeletons, NADPH, and ATP. To see this illustration in color, the reader is referred to the web version
of this article at www.liebertpub.com/ars
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breast, colon, and lung carcinomas (77). Moreover, the over-
expression of IF1 in both normal and cancer cells triggers the
inhibition of the H + -ATP synthase (Fig. 2), the metabolic
switch to an enhanced aerobic glycolysis and the concurrent
increase in the mitochondrial membrane potential due to the
prevention of the backflow of protons into the mitochondrial
matrix (Fig. 2) (77), mimicking the effects of oligomycin (77).
Conversely the silencing of IF1 has the opposite metabolic
effects (77). These findings strongly emphasize the relevance
that the inhibition of the activity of H + -ATP synthase has for
metabolic adaptation of cancer cells and tumor development.
In fact, and in addition to promoting the metabolic switch
observed in cancer cells IF1 simultaneously triggers a mito-
chondrial ROS-mediated nuclear response that switches
on proliferation, invasion, and cell survival (27). The IF1-
mediated adaptive response in colon cancer cells is exerted by
the activation of the canonical NFjB pathway (27). Although
the mechanisms that trigger the upregulation of IF1 in human
carcinomas are presently unknown, its regulation in cancer
provides an explanation of Warburg’s original observation,
further offering a promising target to regulate energy me-
tabolism in carcinomas.
Tumor Microenvironment and the Bioenergetic
Signature of Tumors
The relevance of the cellular environment in cancer pro-
gression is quite well delineated (9, 91) after the pioneer ex-
periments from the Mintz’s laboratory that showed the
development of normal mice frommalignant teratocarcinoma
cells (61). Regarding metabolism, when short-term regulation
of enzyme activities is not enough to cope with the demand
imposed by proliferation or a long-lasting adaptation to a
particular environment, the cells onset the gene expression
programs required for adaptation. Examples that are relevant
to understand the metabolic phenotype of carcinomas are the
adaptations experienced by cells to hypoxia (80, 81), the
metabolic and enzymatic parallelism existing between cancer
cells and embryonic tissues (16), as well as the establishment
of the bioenergetic function of mitochondria during adapta-
tion of mammals to the aerobic extrauterine environment (16).
Hypoxia-inducible factor 1a (HIF-1a) is a transcription
factor induced by low oxygen tension that is overexpressed in
most carcinomas (80, 81). HIF-1a is involved in conferring
resistance against apoptosis and in promoting angiogenesis
and metastasis to cancer cells. HIF-1a promotes the tran-
scriptional activation of many embryonic-type isoforms of the
glycolytic pathway (80, 81). These ‘‘cancer/embryonic’’ en-
zymes differ in their catalytic properties and interacting
partners when compared to the enzymes in normal cells.
Hexokinase II (HKII), that catalyzes the first committed step
of glycolysis, is highly overexpressed in most human carci-
nomas and is tightly bound to mitochondria by its interaction
with VDAC (voltage-dependent anion channel), a protein
component of the PTPC (permeability transition pore
complex), linking in this way energy metabolism to the mi-
tochondrial gate to execute cell death (28, 58, 103). The HK–
VDAC interaction is stimulated by oncogenic Akt signaling
FIG. 2. H1-ATP synthase in normal and tumor cells. Schematic illustration of the organization of the mitochondrial H + -
ATP synthase. Subunits are color-coded and labeled. F1 is the globular catalytic domain made of subunits a, b, and the three
central stalk subunits, c, d, and e. The F0 domain is comprised of the c oligomer, subunit a, and the peripheral stalk subunits
b, d, F6, and OSCP. The minor subunits (e, f, g, and A6L) are not shown, but they all span the membrane and probably bind
close to the a subunit. The rotor is made up of the c-ring and the central stalk. In normal cells, the re-entrance of protons
through the a subunit promotes the rotation of the c-ring and of the attached central stalk, driving the conformational changes
in the b-a-F1-ATPase subunits for synthesis of ATP. In tumor cells, the physiological inhibitor IF1 (yellow) is highly over-
expressed, binding the catalytic a/b interface and preventing synthesis of ATP and promoting mitochondrial hyperpolar-
ization. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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(28, 62, 70), enhancing the glycolytic flux of the cancer cell by
coupling the residual ATP being produced in mitochondria to
the phosphorylation of glucose. This interaction and the
proteins involved have a very relevant impact in metabolic
reprogramming and in controlling the fate of cancer cells (28,
30, 58, 103). Moreover, HIF-1a also controls the expression of
pyruvate dehydrogenase kinase 1 (PDK1) (46), a negative
regulator of the utilization of carbon skeletons in mitochon-
dria of the cancer cell.
Moreover, it is worth emphasizing the parallelism existing
in the expression of pyruvate kinase M2 between cancer cells
and embryos for the control of glycolytic metabolism (17, 56)
and the repression of the bioenergetic function of mito-
chondria in the fetal hepatocyte and hepatomas (16, 21). In
carcinomas and fetal hepatocytes, the complement of mito-
chondria is downregulatedwhen compared to normal tissues.
Moreover, mitochondria in carcinomas have less cristae than
in normal cells (5, 14) consistent with the relevant role played
by H + -ATP synthase in mitochondrial structure (88). In ad-
dition, transcriptomic, proteomic, functional, and structural
studies in human carcinomas invariably indicate that a re-
pressed bioenergetic activity of mitochondria parallels the
activation of glycolysis required for tumor progression (for
review see (15)).
Based on the observation that the expression of H + -ATP
synthase inversely correlates with the activity and expression
of enzymes of the glycolytic pathway during liver develop-
ment, we designed a simple approach to assess the protein
signature of energy metabolism in human carcinomas (14).
The ‘‘bioenergetic signature’’ correlates the amount of the
catalytic b-F1-ATPase subunit of the H + -ATP synthase to the
content of the glycolytic glyceraldehyde-3-phosphate dehy-
drogenase (b-F1-ATPase/GAPDH ratio) in the biopsy. The
bioenergetic signature was shown to be downregulated in
most prevalent human carcinomas. The downregulation of
the bioenergetic signature is a characteristic fulfilled by more
than 97% of the carcinomas analyzed in large cohorts of tu-
mors (3, 13, 14, 43), indicating that it represents a general
phenotypic trait of cancer supporting Warburg’s hypothesis.
These findings have been confirmed (52) and extended to
other carcinomas (see (15) for additional references). More
recently, quantitative assays of the ‘‘bioenergetic signature’’
revealed that tumors from different tissues and/or histologi-
cal types have the same signature of energy metabolism (1, 3).
A functional support to the altered mitochondrial function
in human carcinomas came after the demonstration that the
rates of 18FDG capture assessed by PET imaging in lung
cancer patients inversely correlate with the bioenergetic sig-
nature of the tumors (53). Moreover, the cellular content of
FIG. 3. Mitochondrial activity defines the rate of glucose
consumption. (A) In absence of oxidative phosphorylation
(anaerobiosis, blue lines) the cellular rates of glucose con-
sumption and of lactate production are very high. The
availability of oxygen (aerobiosis, red lines) triggers the onset
of oxidative phosphorylation and the repression of glucose
consumption and lactate production rates. Uncoupling the
mitochondrial proton gradient with 2,4-dinitrophenol (2,4-
DNP) re-establish the original glucose consumption and
lactate production rates. (B) Plots represent the glycolytic
flux measured in breast normal (MCF12) and cancer (NCI-
ADR, HS578T and T47D) cells in the absence (-) or presence
(+ ) of 2,4-DNP. The glycolytic flux is highly increased when
the bioenergetic activity of mitochondria is impaired. To see
this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
Table 1. Genes and Proteins Associated
with Mitochondrial H + -ATP Synthase
Domain Stoichiometry Protein Gene
F1 3 a ATP5A1
F1 3 b ATP5B
F1 1 c ATP5C1
F1 1 d ATP5D
F1 1 e ATP5E
F1 2 IF1 ATPIF1
F0 1 a MT-ATP6
F0 1 b ATP5F1
F0 1 OSCP ATP5O
F0 1 d ATP5H
F0 14 c ATP5G1/G2/G3
F0 1 F6 ATP5J
F0-bound 1 8 or A6L MT-ATP8
F0-bound 1 g ATP5L
F0-bound 1 f ATP5J2
F0-bound 1 e ATP5I
assembly 1 AF1 ATPAF1
assembly 1 AF2 ATPAF2
assembly 1 TMEM70 TMEM70
Summary of the genes, proteins, and stoichiometry of the subunits
and assembly factors of the human H+ -ATP synthase. MT, indicates
encoded in the mitochondrial genome.
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H + -ATP synthase has been shown to directly correlate with
the activity of oxidative phosphorylation, whereas it inversely
correlates with the rate of glucose utilization by aerobic gly-
colysis, strongly supporting the relevance of the Pasteur effect
in cancer biology (76).
Analysis of the bioenergetic signature in large cohorts of
different carcinomas have further emphasized that it affords a
relevant marker for the prognosis of breast (43, 68), colon (3,
14, 52), and lung (13, 53) cancer patients (Fig. 4A). In agree-
ment with these findings, oxidative phosphorylation has been
shown to be the only metabolic pathway whose impairment
correlates with a worse prognosis in colon cancer patients
(83). However, we should note that only a small number of
glycolytic carcinomas result from mutations in nuclear genes
that are related with the metabolic and bioenergetic function
of the organelle (6). Overall, the alteration of the bioenergetic
signature strongly supports a relevant role for the bioener-
getic arrest of mitochondria in cancer cells in order to promote
progression of the disease.
Regulation of H1-ATP Synthase in Human Carcinomas
Despite the relevant role that H + -ATP synthase has in cell
physiology, the regulation of its expression and activity has
been scarcely studied and mostly focused on the heart en-
zyme. As indicated previously (Fig. 2B), the overexpression of
IF1 in human carcinomas downregulates the activity of H + -
ATP synthase (Fig. 4B) (27,77). The main mechanism that
regulates the expression of the catalytic b-F1-ATPase subunit
in fetal liver, during the cell cycle and in rat and human car-
cinomas is exerted at the level of translation (for recent review
see (100)). The 3¢UTR of b-F1-ATPase (b–mRNA) is required
for efficient translation of the transcript and its translation
silencing is observed both in rat and human carcinomas (Fig.
4B) (100). However, translational silencing of b-mRNA in
carcinomas (101) and in development of the human liver (102)
is exerted by different mechanisms.
The AU-rich element (ARE) binding protein HuR, which is
a central regulator of post-transcriptional gene expression,
has been identified as a 3¢UTR b-mRNA interacting protein
(68). Although HuR plays no relevant role in regulating b-F1-
ATPase expression (68), it affords a relevant independent
marker of breast cancer prognosis when studied in combi-
nation with the bioenergetic signature of the tumor, allowing
the identification of patients who are at higher risk of disease
recurrence (68). More recently, the Ras-GAP SH3 binding
protein 1 (G3BP1) has been shown to interact with the 3¢UTR
of b-mRNA (Fig. 4B) (69). G3BP1 is a multifunctional ATP-
dependent helicase with endoribonuclease activity that is
highly overexpressed in breast carcinomas. The interaction of
G3BP1 with b-mRNA specifically represses its translation by
preventing recruitment of the b-mRNA into active polysomes
(69). This finding suggests that G3BP1 participates, at least in
breast cancer, in the downregulation of b-F1-ATPase expres-
sion and hence in promoting the metabolic switch in carci-
nomas. In this context, the identification of the b-mRNA
binding proteins (69) and miRNAs (102) that interact and
presumably hamper translation of the transcript represents a
crucial step in order to understand the bioenergetic pheno-
type of different cancer cells (Fig. 4B).
Another mechanism used by cancer cells to silence b-F1-
ATPase expression has been described in chronic myeloid
leukemia (51). In this situation, downregulation of b-F1-
ATPase is exerted by limiting the amount of the mRNA by
hypermethylation of the promoter of the ATP5B gene (Fig. 4B)
(51). In addition, it is likely that mutations that result in
the inactivation of the genes involved in the biogenesis of
FIG. 4. H1-ATP synthase in cancer biology. (A) The bio-
energetic signature (b-F1-ATPase/GAPDH ratio) of colon
carcinomas is a significant marker of the prognosis of colon
cancer patients [re-drawn from (3)]. (B) Different mecha-
nisms affect the activity and/or content of H + -ATP synthase
in human carcinomas. The overexpression of the ATPase
inhibitor factor 1 (IF1) in human carcinomas limits the ac-
tivity of the H + -ATP synthase and promotes the metabolic
switch in cancer cells. Silencing of b-F1-ATPase mRNA
(b-mRNA) translation in carcinomas is mediated by the in-
teraction of the mRNA with different mRNA binding pro-
teins such as G3BP1. The reduction of b-mRNA availability
by hypermethylation of the promoter of b-F1-ATPase gene
(ATP5B) in chronic myeloid leukemia cells has also been
described. To see this illustration in color, the reader is re-
ferred to the web version of this article at www.liebertpub
.com/ars
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H + -ATP synthase (Table 1), also contribute to the down-
regulation of this protein complex in a limited number of
carcinomas. Overall, these findings illustrate the need of fur-
ther basic studies aimed at characterizing the complexity of
the cellular response required for mitochondrial biogenesis.
These studies will allow understanding the alterations of the
mitochondrial proteome that specifically affect the content/
activity of the H + -ATP synthase in different carcinomas
(Fig. 4B).
Oxidative Phosphorylation and Cell Death Are
Molecularly and Functionally Integrated
In addition to the role of mitochondria in energy metabo-
lism, regulation of cell death has emerged as another major
function of the organelle. These two master tasks of mito-
chondria are molecularly and functionally integrated despite
the many forms and shapes of cell death (Fig. 5). In particular,
molecular components that participate in oxidative phos-
phorylation, such as cyt c, AIF, and subunits of H + -ATP
synthase, are required for the efficient execution of cell death
(Fig. 5) (55, 71, 92). Conversely, Bcl-xL, a protein that partic-
ipates in preventing apoptosis (Fig. 5), has been recently
shown to interact with b-F1-ATPase to regulate the efficiency
of energymetabolism (2). Likewise, the tumor-suppressor p53
has been suggested to mediate the regulation of mitochon-
drial energy metabolism via the downregulation of parkin
(104) (Fig. 5). Moreover, Bax needs H + -ATP synthase to ex-
ercise its pro-apoptotic function (55). More recently, a fun-
damental relationship between mitochondrial bioenergetics
and the tumor response to cytotoxic chemotherapy has been
elegantly documented (64) and deserves further mechanistic
characterization in future studies.
ATP and reactive oxygen species (ROS) are products of
mitochondrial function (Fig. 1) that can hold the balance be-
tween apoptosis, necrosis, or other unconventional types of
cell death such as autophagy (32, 34, 50, 66). In apoptosis, a
sufficient supply of ATP is necessary to favor apoptosome
formation to trigger the activation of caspases, chromatin
condensation, and the correct execution of cell death (34) (Fig.
5). On the contrary, when ATP levels are limited, a typical
apoptotic stimulus causes cell necrosis (Fig. 5). Necrosis has
been considered an uncontrolled mode of cell death for years.
However, rising evidence suggests that necrosis is regulated
FIG. 5. Overview of the integration of energy metabolism and cell death. The scheme shows the connections between
energy metabolism and the three major cell-death pathways: apoptosis (red), necrosis (blue), and autophagy (green). The
availability of oxygen and glucose could trigger cell death or signal for proliferation. The cellular levels of reactive oxygen
species (ROS) produced during mitochondrial respiration determine cell fate. The depicted high and low ROS levels should
be considered above a basal ROS production as a result of an impaired mitochondrial function. Low levels of ROS are
fundamental for transcription of genes involved in cell growth, whereas higher ROS levels results in oxidative damage that
can participate in apoptosis, necrosis, or autophagy. Similarly, ATP generated by glycolysis and oxidative phosphorylation
holds the balance between life and death. High ATP amounts are necessary for cell survival and the inhibition of autophagy,
but also for the correct execution of apoptosis. When ATP is low, such as during PARP-1 hyper-activation, cells die by
necrosis. Cyt c, AIF, and H + -ATP synthase are important proteins of oxidative phosphorylation that have emerged as
regulators of apoptosis and necrosis. Bax, p53, and Bcl-xL are well known pro- and anti-apoptotic proteins that have been
recently described as regulators of oxidative phosphorylation. To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
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by a signaling pathway tightly connected with energy me-
tabolism (32). Indeed, deprivation of oxygen or glucose are
well known stimuli to induce necrosis in different experi-
mental models (Fig. 5) (32). Moreover, interfering with gly-
colysis in cancer cells triggers massive ATP depletion and
necrotic cell death (75). Upon massive DNA damage, the
hyperactivation of PARP-1 leads to depletion of intracellular
ATP, resulting in necrosis (Fig. 5) (25). The cell death pathway
prompted by excessive PARP-1 activation has been conserved
throughout evolution of multicellular organisms, perhaps
for its ability to eliminate cells that have undergone exces-
sive genotoxic stress and are therefore at risk of neoplastic
transformation (25).
Low cellular ATP levels can also induce autophagy (50). It
has been described that AMP-activated protein kinase
(AMPK), which is activated when the H + -ATP synthase is
inhibited, has critical roles both in reprogramming metabo-
lism and in the induction of autophagy (60). A recent report
linked mitochondrial morphology to the regulation of both
ATP production and response to autophagy (33). In fact,
when autophagy is prompted, mitochondria elongate
through unobstructed mitochondrial fusion (33). Elongated
mitochondria have more cristae, increased levels of dimer-
ization and activity of H + -ATP synthase, maintain ATP pro-
duction, and are protected from autophagic degradation (33).
Conversely, when mitochondrial elongation is inhibited, the
ATP levels fall down and the cell die by starvation-induced
death, suggesting the existence of a dynamic feedback be-
tween autophagy and cellular energy balance (85).
As a product of respiration, mitochondria produce ROS at
complex I and complex III of the respiratory chain (Fig. 1).
ROS are highly reactive molecules that can oxidize DNA,
proteins, and lipid,s and have been implicated in the oxidative
damage that accompanies normal physiological ageing, can-
cer, and neurodegeneration. The cellular response to ROS
depends on its intensity (11, 24, 66). A high ROS signal due to
cellular or metabolic stress and/or in response to chemo-
therapy could trigger cell death by apoptosis, necrosis, or
autophagy after integration of the various signaling mole-
cules (ATP, ROS, O2, glucose,.) involved in these processes
(Fig. 5). In any case, the cell fate is tightly modulated by the
cellular amount of ROS, which act to tweak the balance be-
tween survival and cell death (Fig. 5) (66). In contrast, a low
level of mitochondrial ROS production signals the gene
transcription programs involved in cell proliferation (Fig. 5).
In fact, ROS production in human carcinomas (89) leads to the
activation of the signaling networks promoting tumorigenesis
and metastasis (42, 97). Consistently, the low ROS produced
by mitochondria in response to the overexpression of IF1 has
emerged as a powerful stimulus for the induction of cellular
proliferation in cancer cells (27). This implies that cancer cells
exert a tight regulation of mitochondrial ROS production and
of the antioxidant machinery to increase their chances of
survival (11). Overall, we support that enhancement of mi-
tochondrial metabolism acts as a tumor suppressor by pro-
moting cell death essentially by apoptosis in normal genetic
backgrounds. In contrast, mitochondrial metabolism can be-
come tumorigenic by stimulating proliferation andmetastasis
when genetic alterations or the deregulation of a protein, such
as IF1, participate in signaling an oncogenic phenotype via
ROS production (27, 42, 97). In other words, genetic lesions
and/or IF1 can promote the conversion of mitochondrial
activity from a tumor suppressor into a tumor promoter,
highlighting the complex role of mitochondrial activity in
tumor progression.
Excessive ROS production in mitochondria could result
from genetic defects affecting components of the respiratory
chain, by the inhibition of oxidative phosphorylation medi-
ated by hypoxia, by different chemotherapeutic agents, or by
the induction of IF1 in cancer cells (Fig. 2) (77). In these situ-
ations, the mitochondrial membrane potential (DCm) is in-
creased and the production of ROS enhanced (27, 77, 78).
Therefore, DCm represents an additional link between energy
metabolism, ROS production, and cell fate. In fact, the in-
duction of apoptosis by many different stressors invariably
results in the collapse of DCm. However, a preceding event
before DCm collapses is a transient mitochondrial hyperpo-
larization (47, 55, 78) and the subsequent production of a ROS
signal (39, 78). Remarkably, oligomycin prevents mitochon-
drial hyperpolarization and ROS production in response to a
death stimulus delaying the execution of apoptosis (Fig. 6)
(55, 78). Moreover, the generated ROS oxidize cellular con-
stituents (78), facilitating in this way the release of mito-
chondrial proteins that swamp the cells into death.
Oligomycin prevented also these modifications (78), high-
lighting the deep connection that exists between energy
FIG. 6. The activity of H1-ATP synthase regulates the
efficiency of cell death. Illustration of the rapid (*3 h)
staurosporine (STS)-induced cell death in liver C9 cells.
Mitochondria-tagged gfp cells were treated with STS in the
absence or presence of oligomycin (OL) or left untreated
(CRL). STS induces the rapid fragmentation and swelling of
mitochondria, resulting in significant nuclear DNA frag-
mentation and cell death. Treatment of the cells with oligo-
mycin (OL) was unable to prevent the changes in
mitochondrial morphology but significantly delayed nuclear
DNA-fragmentation and cell death. To see this illustration in
color, the reader is referred to the web version of this article
at www.liebertpub.com/ars
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metabolism, H + -ATP synthase, and the correct execution of
cell death (Fig. 5).
The Tumor Suppressor Function
of Mitochondrial Activity
Tumor suppressors such as Pten, p53, Ink4a, and Arf are
known to exert a beneficial pleiotropic effect in cell physiology
against aging and metabolic disease, in addition to provide
protection against cancer (82). Activation of mitochondrial
metabolism is a likely mechanism of their action (54, 67).
Sirtuins are NAD + -dependent protein deacetylases that reg-
ulate longevity and a wide range of intracellular processes
(35). Studies in mouse models with genetically modified
SIRT1 levels strongly support the in vivo tumor suppressor
activity of SIRT1 (see (38) and references therein). In this re-
gard, the mitochondria-localized SIRT3 has been shown to
exert its tumor suppressor function by maintaining mito-
chondrial integrity and metabolism (45) and, consistently,
resveratrol has been shown to improve mitochondrial func-
tion and to protect against metabolic disease by activating
SIRT1 and PGC-1a (48).
Consistent with the implication of mitochondrial activity
and of H + -ATP synthase in cell death, there is a large body of
data supporting that mitochondrial function, both under ba-
sal conditions or in response to chemotherapeutic agents, acts
as a tumor suppressor. In this regard, the oxidation of mito-
chondrial substrates is known to halt malignant growth. The
oxidation of fatty acids by the mitochondrial b-oxidation
pathway is known to engage cancer cells into death (7, 98).
Moreover, the inhibition of alanine aminotransferase, that
slows down aerobic glycolysis and promotes an increase in
cellular respiration by the oxidation of glutamine, has been
shown to diminish cellular as well as tumor growth (8). Since
cancer cell metabolism is characterized by a limited activity of
oxidative phosphorylation to minimize oxidative stress dur-
ing proliferation (10, 15), a likely mechanism that explains the
preferential death of cancer cells when forced to oxidize mi-
tochondrial substrates is by the overproduction of superoxide
radical as a result of the stimulation of mitochondrial
metabolism (8, 98).
Likewise, the von Hippel-Lindau (VHL) tumor suppressor
activates oxidative phosphorylation and when injected into
nude mice retards tumor formation and growth (41). In
agreement with Warburg’s postulates, a defective oxidative
phosphorylation due to a deficiency in frataxin is known to
favor early tumor progression in Friedreich ataxia patients, as
well as in the liver of frataxin-KO mice (90). Conversely, the
overexpression of frataxin in colon cancer cells triggers an
increase in oxidative metabolism concurrent with a decrease
in tumorigenicity (79). A dysfunctional oxidative phosphor-
ylation has been shown to promote cellular proliferation and
invasion (4, 27, 93). Conversely, the activation of pyruvate
metabolism in mitochondria promotes the activity of
FIG. 7. Energy metabolism can gear the cell-death pathway of cancer cells. Cancer cells have different susceptibility to
death stimulus as a result of their metabolic phenotype. A first event to death after priming the cells is the rapid dismantling
and fragmentation of the mitochondrial tubular network into small mitochondria (blue). Tumor cells with relevant oxidative
phosphorylation (OXPHOS) (i.e., high bioenergetic signature) (a)will respond with a burst in ROS production contributing to
the oxidation of mitochondrial proteins (red dots) and their release from mitochondria to effectively swamp the cells into
apoptosis (fragmented nucleus in blue). In contrast, cancer cells that have a high glycolytic metabolism (i.e., low bioenergetic
signature) (b) will not respond with ROS production to a conventional chemotherapeutic agent, resulting in resistance to cell
death. In this situation, it is suggested that metabolic inhibitors interfering with glycolysis (b1) (bromopyruvate, BrPy;
iodoacetate, IA) to produce a metabolic catastrophe by depletion of cellular ATP levels can promote cell death by necrosis.
Alternatively, treatment of highly glycolytic tumors with compounds that could activate the metabolism of pyruvate in
mitochondria or the overall oxidative phosphorylation (b2) (dichloroacetate, DCA) could revert the metabolic phenotype of
the cancer cell to produce ROS and the execution of apoptotic cell death. To see this illustration in color, the reader is referred
to the web version of this article at www.liebertpub.com/ars
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oxidative phosphorylation and halts cellular proliferation and
invasion (57) indicating the beneficial effect that restoring
mitochondrial metabolism has in tumor formation.
Hence, we suggest that the tumor suppressor function of
the activity of mitochondrial metabolism impinges in at least
two of the hallmarks of the cancer phenotype by inhibiting
cellular proliferation and activating apoptosis. Indeed, the
activation of mitochondrial metabolism limits the supply of
building blocks for biosynthetic purposes as a result of the
burning of carbon skeletons in mitochondria, promoting en-
ergy expenditure, and preventing nutrient storage and its
associated damage (67). Moreover, the activation of mito-
chondrial metabolism generates sufficient ROS by the func-
tioning of mitochondrial respiration to allow the execution of
cell death programs in normal genetic contexts. Themolecular
mechanisms involved need to be unveiled in future studies.
However, both genetic (18) and pharmacological (94) studies
have shown that the PGC1a-mediated improvement of mi-
tochondrial activity and metabolism hamper cancer progres-
sion by increasing apoptosis and decreasing cellular
proliferation and invasion. In particular, PGC1a protects
against colon cancer by promoting ROS accumulation and the
induction of mitochondria-mediated apoptosis (18), illustrat-
ing a direct connection between mitochondrial function and
its tumor suppressor activity.
Taken together, the above findings support that interfering
with the bioenergetic function of mitochondria predisposes to
cancer development and tumor growth. Since treatment of
cancer cells with dichloracetate (DCA) triggers a switch to a
mitochondrial-dependent pathway of energy provision and
promotes in vivo tumor regression (59, 76), the activation of
mitochondrial function could represent a successful alterna-
tive for the treatment of cancer (Fig. 7). In this regard, the
bioenergetic signature has been shown to predict the apo-
ptotic response to chemotherapy in various cancer cells (37,
75, 84), as well as in colorectal carcinomas (52). Overall, these
findings highlight the role of mitochondria in the epigenetic
regulation of tumorigenesis and suggest that repression of
oxidative phosphorylation is a prerequisite for tumor devel-
opment (76). On the other hand, knocking down the glycolytic
lactate dehydrogenase in mouse mammary tumor cells trig-
gers an increase in mitochondrial function, a compromised
ability to proliferate under hypoxia, and a reduction in the
tumorigenicity of the cells (23). These results illustrate the
tight connection that exists between glycolysis and oxidative
phosphorylation and confirm that the inhibition of glycolysis
could also provide a promising target to restrict proliferation
of cancer cells (Fig. 7). In fact, we have shown that the bio-
energetic signature of colon cancer cells predicts the potential
to execute necrotic cell death in response to inhibitors of
glycolysis (75).
We propose that energy metabolism offers an attractive
target for cancer treatment, perhaps when used in combina-
tion therapy, because it tackles a universal trait of the disease
that could define the response and cell death pathway to
chemotherapy (Fig. 7). Cancer cells with active oxidative
phosphorylationwill produce ROS in response to therapy and
the resulting oxidative damage will engage cells into apo-
ptosis (Fig. 7). In contrast, cancer cells with a predominant
aerobic glycolysis are resistant to conventional therapy be-
cause of their impossibility to produce mitochondrial ROS
(Fig. 7) (78). Therefore, we suggest that the strategy to follow
with highly glycolytic tumors could be the activation of oxi-
dative phosphorylation that might restore the cell sensitivity
to apoptotic inducers and/or the employment of agents that
by prompting ametabolic catastrophewill lead to cell necrosis
(Fig. 7).
Final Remarks
Research over the last 10 years has put back into stage the
relevance of energy metabolism in cancer biology. The in-
creased aerobic glycolysis and restrained bioenergetic func-
tion of mitochondria in cancer cells is a required metabolic
condition for cellular proliferation. In general, tumor energy
metabolism is a reversible phenotypic trait of the cancer cell
due to its adaptation to a particular environment. Limiting
the bioenergetic activity of mitochondria, and specifically of
H + -ATP synthase, contributes to tumor growth because oxi-
dative phosphorylation is required for efficient execution of
cell death. Two independent mechanisms specifically target
the activity and the cellular content of the mitochondrial
H + -ATP synthase to favor an increase in aerobic glycolysis
and the restrained oxidative phosphorylation in cancer. The
bioenergetic signature of the tumor has clinical utility for the
prognosis of cancer patients and could aid in the establishment
of new anti-tumor therapies. However, the activity and mo-
lecular composition of mitochondria is cell-type specifically
expressed. Therefore, basic studies aimed at characterizing the
complexities of the cellular responses needed for mitochon-
drial biogenesis are required to understand the alterations of
the content/activity of H+ -ATP synthase in cancer. Moreover,
unveiling the different mechanisms and components that
participate in the tumor suppressor function of mitochondrial
activity is also needed. These studies could gear the estab-
lishment of new therapeutic strategies aimed at combating the
progression of the disease using energy metabolism as target.
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Abbreviations Used
DCm¼mitochondrial membrane potential
AIF¼ apoptosis inducing factor
AMPK¼AMP-activated protein kinase
ANT¼ adenine nucleotide translocase
ATP¼ adenosine triphosphate
Bax¼BCL2-associated X protein
Bcl-xL¼B-cell lymphoma-extra large
BrPy¼ bromopyruvate
Cyt c¼ cytochrome c
DCA¼dichloroacetate
2,4-DNP¼ 2,4-dinitrophenol
18FDG¼ 18F-desoxiglucose
HIF1a¼hypoxia inducible factor 1
G3BP1¼Ras-GAP SH3 binding protein 1
IF1¼ATPase inhibitory factor 1
IA¼ iodoacetate
OL¼ oligomycin
OSCP¼ oligomycin sensitivity conferring protein
OXPHOS¼ oxidative phosphorylation
PARP1¼poly-ADP ribose polymerase 1
PET¼positron emission tomography
PPP¼pentose phosphate pathway.
Pten¼phosphatase and tensin homolog
ROS¼ reactive oxygen species
SIRT¼ sirtuin
STS¼ staurosporine
TCA¼ tricarboxylic acid cycle
3¢UTR¼ 3¢untranslated region
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